BioSig Strengthens Marketing and Sales Teams, Appoints National Account Executives to Scale Commercial Growth

Rhea-AI Summary

BioSig Technologies (NASDAQ: BSGM) recently announced significant enhancements to its commercial strategy, focusing on expanding its sales and marketing teams. The company has doubled its sales force and plans to triple it by Q4 2022, appointing new National Account Executives to drive the adoption of its innovative PURE EP™ System. Additionally, a newly strengthened marketing team will implement a comprehensive strategy to boost brand equity and market presence. Key clinical data demonstrating a 75% improvement in signal quality from the PURE EP™ System has been published, further validating its competitive edge.

Positive

• Doubled sales organization, with plans to triple before Q4 2022, indicating strong growth strategy.
• New National Account Executives strategically placed to enhance sales and market expansion.
• Investment in top-tier marketing talent to improve brand equity and competitive positioning.
• Published clinical data showing 75% improvement in intracardiac signal quality, enhancing product credibility.

Negative

• None.

Westport, CT, Aug. 30, 2022 (GLOBE NEWSWIRE) --

• Company increases sales efforts and strategy, adds new National Account Executives to accelerate commercial growth

• Strengthens marketing team with new marketing and communications programs highlighting competitive market advantage

BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced that it has expanded its marketing and sales teams to scale and support the national commercial rollout of its PURE EP™ System.

BioSig recently doubled the size of its sales organization, with plans of tripling it before the fourth quarter of this year. The Company appointed a new team of National Account Executives who will be strategically located throughout the U.S. to support and accelerate sales growth and adoption of the PURE EP™ System. The new sales executives will expand the Company’s growing commercial pipeline, as it continues to see an increase in medical centers entering into 60-day evaluation agreements for its novel signal processing technology.

Additionally, BioSig has expanded its marketing team, with investment in top-tier industry talent that will help drive and enhance the Company’s brand equity and awareness to better reflect the Company’s values. These new efforts include a fully integrated marketing and communications strategy that will support the commercial team and should provide the tools to increase BioSig’s competitive position in the market.  

“As a growing enterprise, we are dedicated to sourcing, developing, and retaining the best talent for our company. I view our recent investment in our commercial, sales, and marketing teams as a complimentary catalyst for BioSig’s new commercial strategy and longterm growth. We are thrilled to have attracted these outstanding industry leaders, and look forward to leveraging their wealth of knowledge and expertise,” said Gray Fleming, Chief Commercialization Officer, BioSig Technologies, Inc.

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company's first product, PURE EP™ System, is a novel signal processing and acquisition platform designed to extract advanced diagnostic and therapeutic data that enhances physician workflow and increases throughput. PURE EP™ was engineered to address the limitations of existing EP technologies by empowering physicians with superior signals and actionable insights. The Company is in a national commercial launch of the PURE EP™ System. The technology is in regular use in some of the country’s leading centers of excellence, including Mayo Clinic, and Texas Cardiac Arrhythmia Institute at St. David’s Medical Center.

Clinical data acquired by the PURE EP™ System in a multi-center study at centers of excellence including Texas Cardiac Arrhythmia Institute at St. David’s Medical Center  was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP(T.M.) signals over conventional sources.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market conditions and the Company’s intended use of proceeds, (ii) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (iii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iv) difficulties in obtaining financing on commercially reasonable terms; (v) changes in the size and nature of our competition; (vi) loss of one or more key executives or scientists; and (vii) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

FAQ

What recent changes has BioSig Technologies made to its sales strategy?

BioSig Technologies has doubled its sales organization and plans to triple it by Q4 2022, appointing new National Account Executives to enhance sales efforts.

What is the PURE EP™ System and how has it been received in clinical settings?

The PURE EP™ System is a novel signal processing platform that has shown a 75% improvement in intracardiac signal quality in recent clinical studies, gaining traction in leading medical centers.

What are the new marketing initiatives being undertaken by BioSig Technologies?

BioSig is investing in a fully integrated marketing and communications strategy aimed at increasing brand equity and awareness to support its commercial growth.

How has BioSig Technologies' clinical data been received?

Clinical data from the PURE EP™ System has been published, showing a 93% consensus among blinded reviewers on the improvement in signal quality, bolstering the system's market potential.